Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250496 · ClinicalTrials.gov registry record · Phase 4
Study With Aminophylline to Attenuate of the Side Effects of Regadenoson
A Phase 4 study, sponsored by Rush University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
NCT01250496: Clinical Trial Phase 4 study, sponsored by Rush University Medical Center.
NCT01250496 is a Phase 4 study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 248 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01250496, a Phase 4 study, was terminated before completion, sponsored by Rush University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
Study Summary
The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson.
Primary Outcome
Patients will be surveyed for these symptoms following to the completion of the cardiac stress testing procedure and prior to discharge from the laboratory.
Interventions
- DRUG Placebo
- DRUG Aminophylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
Why NCT01250496 stopped before completion
NCT01250496 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01250496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01250496 about?
NCT01250496 is a clinical study titled "Study With Aminophylline to Attenuate of the Side Effects of Regadenoson". The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson.
What is the current status of trial NCT01250496?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 2010-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01250496?
The interventions under investigation include: Placebo (DRUG), Aminophylline (DRUG).
Who is sponsoring clinical trial NCT01250496?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01250496's enrollment target sits among peer trials
248 353rd of 2000 higher than 1,646 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia